Figure 1From: Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trialPlacebo- and baseline-corrected change in QTcI. (a) Placebo- and baseline-corrected change in QTcI for each time point in each treatment group. (b) Pharmacokinetic/pharmacodynamics relationship: placebo- and baseline-corrected change in QTcI versus netupitant plasma concentrations and (c) versus palonosetron plasma concentrations.Back to article page